Humanity is entering into a post-antibiotic era. The global health crisis caused by antibiotic-resistant bacteria is growing at an alarming pace. “The Review on Antimicrobial Resistance (AMR)” commissioned by the UK Prime Minister to a team led by the economist Jim O’Neill concluded in 2016 that if we do not take new measures to bring to the market solutions at higher speed, 10 million people/year will die of uncurable infections globally by 2050. A crisis of bigger proportions than that produced by Covid-19 in 2020-2021.


New solutions must combine prevention and treatment. In 2021, treatment options alternative to antibiotics (bacteriophages, antimicrobial peptides, lysines, etc.) are still far from high-scale human trials. Vaccines, for establishing protective immunity against the most worrisome superbacteria, are the first line of measures that will be tested extensively in humans and will reach people in urgent need. 


CARB-X awarded Vaxdyn in 2020 up to US$1.01 million, plus an additional $6.36 million if certain project milestones are met, to develop a new vaccine to prevent life-threatening drug-resistant infections, including pneumonia, until completion of the first proof of principle in humans (Phase 1).

CARB-X is a consortium led by Boston University and funded by a global partnership. Funding for the Vaxdyn project is provided by the Biomedical Advanced Research and Development Authority (BARDA), the Wellcome Trust, Germany’s Federal Ministry of Education and Research (BMBF), the UK Government’s Global AMR Innovation Fund (GAMRIF), and the Bill & Melinda Gates Foundation.

The non-dilutive, non-refundable funds awarded by CARB-X are complemented by private investors who joined Vaxdyn’s founders in 2020 and 2021. Seed capital has been provided by The Mind the Gap investment vehicle led by The Botín Foundation (Spain, linked to the Bank of Santander) and yet undisclosed European venture-capital and industrial groups.

For vaccine development, Vaxdyn is working with its key partners, the National Center of Microbiology of the Spanish Institute of Health Carlos III and Laboratorios Reig Jofré (Barcelona).


Investors will be welcome to join us in the next round for execution of the first human trial. 

This opportunity is backed by:

  • Innovative and validated technology for a public health highly unmet need
  • Project and Plan validated with highly qualified experts in the field in the Advisory Board
  • Substantial non-dilutive grant resulting in highly discounted equity
  • The sponsorship of CARB-X and current talks with pharmaceutical companies support the potential exit and ROI of investment